140,400 Cellebrite DI Ltd. $CLBT Shares Sold by CenterBook Partners LP

CenterBook Partners LP lessened its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 59.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,126 shares of the company’s stock after selling 140,400 shares during the period. CenterBook Partners LP’s holdings in Cellebrite DI were worth $1,071,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. PNC Financial Services Group Inc. increased its holdings in shares of Cellebrite DI by 59.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock valued at $103,000 after purchasing an additional 2,785 shares in the last quarter. Elevation Wealth Partners LLC boosted its holdings in Cellebrite DI by 93.3% during the third quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company’s stock worth $66,000 after buying an additional 2,816 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in Cellebrite DI by 91.1% during the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock worth $105,000 after buying an additional 3,626 shares in the last quarter. Moody National Bank Trust Division boosted its holdings in Cellebrite DI by 7.6% during the second quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock worth $886,000 after buying an additional 4,284 shares in the last quarter. Finally, Quantinno Capital Management LP acquired a new stake in Cellebrite DI during the first quarter valued at $150,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Insider Activity at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,562 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the completion of the sale, the executive owned 427,128 shares of the company’s stock, valued at approximately $4,800,918.72. The trade was a 2.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO David Gee sold 4,323 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $11.36, for a total transaction of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares of the company’s stock, valued at $1,536,792.16. This represents a 3.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 56,516 shares of company stock worth $636,660 over the last 90 days. 5.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Lake Street Capital cut their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Weiss Ratings cut Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. Finally, DA Davidson restated a “buy” rating and set a $15.00 target price on shares of Cellebrite DI in a research report on Tuesday, September 15th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average target price of $16.70.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $12.64 on Wednesday. The stock has a market capitalization of $3.15 billion, a PE ratio of 45.36, a price-to-earnings-growth ratio of 1.95 and a beta of 1.06. The business has a 50 day simple moving average of $11.61 and a 200-day simple moving average of $13.29. Cellebrite DI Ltd. has a 12 month low of $9.58 and a 12 month high of $19.98.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.